Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Income from Continuing Operations for 4 consecutive years, with 2260750.0 as the latest value for Q4 2020.

  • Quarterly Income from Continuing Operations fell 84.57% to 2260750.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was 6508875.0 through Dec 2020, down 50.54% year-over-year, with the annual reading at 15585619.0 for FY2024, 85.94% down from the prior year.
  • Income from Continuing Operations hit 2260750.0 in Q4 2020 for Monopar Therapeutics, down from 1647979.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 373839.0 in Q1 2017 to a low of 14897530.0 in Q3 2017.
  • Historically, Income from Continuing Operations has averaged 1912152.75 across 4 years, with a median of 929233.5 in 2018.
  • Biggest YoY gain for Income from Continuing Operations was 95.52% in 2018; the steepest drop was 140.01% in 2018.
  • Year by year, Income from Continuing Operations stood at 736800.0 in 2017, then decreased by 25.73% to 926358.0 in 2018, then tumbled by 32.23% to 1224895.0 in 2019, then tumbled by 84.57% to 2260750.0 in 2020.
  • Business Quant data shows Income from Continuing Operations for MNPR at 2260750.0 in Q4 2020, 1647979.0 in Q3 2020, and 1464132.0 in Q2 2020.